Daptomycin: a novel agent for Gram-positive infections
- 1 August 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 8 (8), 1223-1238
- https://doi.org/10.1517/13543784.8.8.1223
Abstract
The alarming increase in the incidence of Gram-positive infections, including those caused by resistant bacteria, has sparked renewed interest in novel antibiotics. One such agent is daptomycin, a novel lipopeptide antibiotic with proven bactericidal activity in vitro against all clinically relevant Gram-positive bacteria. These include resistant pathogens, such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide intermediately susceptible Staphylococcus aureus (GISA), coagulase-negative staphylococci (CNS) and penicillin-resistant Streptococcus pneumoniae (PRSP), for which there are very few therapeutic alternatives. Daptomycin provides rapid, concentration-dependent killing and a relatively prolonged concentration-dependent post-antibiotic effect in vitro. Spontaneous acquisition of resistance to daptomycin occurs rarely. Daptomycin exhibits linear pharmacokinetics, minimal accumulation with once-daily dosing, and low plasma clearance and volume of distribution. Phase II clinical trials indicate that daptomycin at doses of 2 mg/kg q24 h and 3 mg/kg q12 h is efficacious against skin and soft tissue infections and bacteremia, respectively. In addition, results in endocarditis suggested potential efficacy with higher doses. On the basis of clinical trials to date, it appears that daptomycin has an excellent safety profile, with the incidence and nature of serious adverse events comparable to those observed with conventional therapy. Adverse events associated with other classes of antimicrobials (nephrotoxicity, local irritation, ototoxicity, hypersensitivity, and gastrointestinal effects) were uncommon with daptomycin. Minimal skeletal muscle toxicity was seen at only the highest dose tested (4 mg/kg q12 h), predicted by elevations in serum creatinine phosphokinase, and readily reversible upon discontinuation of treatment. There were no signs of toxicity in cardiac or smooth muscle. Phase II and III clinical trials are underway to evaluate daptomycin for the treatment of Gram-positive bacteremia and complicated skin and soft tissue infections, respectively. Daptomycin holds promise as a rapidly acting and highly effective antibiotic for Gram-positive infections.Keywords
This publication has 44 references indexed in Scilit:
- Identification of daptomycin-binding proteins in the membrane of Enterococcus hiraeAntimicrobial Agents and Chemotherapy, 1995
- The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesisJournal of Antimicrobial Chemotherapy, 1993
- Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic modelAntimicrobial Agents and Chemotherapy, 1992
- Daptomycin disrupts membrane potential in growing Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991
- Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugsAntimicrobial Agents and Chemotherapy, 1991
- Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)Antimicrobial Agents and Chemotherapy, 1990
- In vitro activity of LY146032 against gram-positive bacteriaDiagnostic Microbiology and Infectious Disease, 1988
- Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendationsAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of LY146032 against staphylococci, streptococci, and enterococciAntimicrobial Agents and Chemotherapy, 1986
- In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibioticAntimicrobial Agents and Chemotherapy, 1986